A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease
- 12 November 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 24 (11) , 1261-1269
Abstract
Alzheimer's disease can cause dementia through brain matter degradation. This study investigates the monoclonal antibody usage for AD treatment, following PRISMA 2020 guidelines, and aims to discern the monoclonal antibody that offers the optimal balance of efficacy and safety for individuals with AD. A systematic search was conducted across databases such as PubMed, Cochrane Library, and clinical trial registries for randomized controlled trials. The quality of studies was assessed using the Cochrane risk of bias 2 tool. Cognitive function and daily activities were evaluated using MMSE, ADAS-Cog, and CDR-SB test data. According to CDR-SB measurements, lecanemab showed effectiveness in reducing brain amyloid and cognitive decline, with a change from baseline of 1.21. Aducanumab resulted in a decrease of -0.39 (-22%). Bapineuzumab showed no significant benefit, with scores of 2.4 (2.8). Gantenerumab, scoring 1.69 (1.37, 2.01), reduces amyloid, particularly in early Alzheimer's stages. Crenezumab was ineffective, with a score of 3.61. The findings provide various perspectives. Lecanemab showed the most promise in brain amyloid reduction and decelerating cognitive decline compared to the other therapies. Further research is needed, highlighting the necessity of AD therapeutic research to alter AD's trajectory and provide reliable treatment. www.crd.york.ac.uk/prospero identifier is CRD42024504358.Keywords
This publication has 38 references indexed in Scilit:
- Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priorsAlzheimer's & Dementia, 2023
- Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease ModificationDrugs, 2023
- The role of A$\beta $ and Tau proteins in Alzheimer’s disease: a mathematical model on graphsJournal of Mathematical Biology, 2023
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease TherapeuticsDrugs, 2023
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer DiseaseJAMA Neurology, 2021
- The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeuticsActa Neuropathologica, 2020
- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and PromiseBiological Psychiatry, 2018
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With GantenerumabArchives of Neurology, 2012